Sanofi Consumer Healthcare India Ltd. announced it’s Q1 results with PAT at Rs. 50 crore, which stands 12.9% above last quarter of Q4 2024. With an increase of Rs. 2.4 per share, landing the EPS at Rs. 21.7. The company reported revenue from operations of Rs. 172.6 crore.

Commenting on the results, Himanshu Bakshi, Managing Director, Sanofi Consumer Healthcare India Limited, “We continue to focus on strengthening our operations and continues to bring superior, simple and accessible products that enable consumers to control their own health. Our commitment to delivering high-quality, science-backed products remains at the core of our integrated growth strategy.”

The Q1 2025 also witnessed a successful launch of Allegra D, an addition to the existing portfolio of Allegra variants in India; a brand with over 25 years legacy in India.

Q1 2025 and Q1 2024 are not directly comparable, due to demerger and voluntary product recall of certain variants of key brands.